BioNTech to acquire CureVac for $1.25 billion ... certain of its affiliates and expected to close in 2025 CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into ...

(RTTNews) - BioNTech SE (BNTX) and CureVac N.V. (CVAC ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

CureVac (CVAC) stock jumps as BioNTech (BNTX) agrees to acquire in an all-stock deal worth $1.25B. Read more here.

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its ...

COVID success story BioNTech (Nasdaq: BNTX) is to buy fellow German mRNA company CureVac (Nasdaq: CVAC). Shares in the latter ...

BioNTech (NASDAQ:BNTX) has agreed to acquire its German rival CureVac (NASDAQ:CVAC) in an all-stock transaction worth nearly ...

CureVac NV (NASDAQ:CVAC) stock soared 29.5% on Thursday pre-market trading after German biotech firm BioNTech SE (NASDAQ:BNTX) said it would acquire the company for approximately $1.25 billion.

BioNTech, one of the first companies worldwide to develop an effective coronavirus vaccine, is looking to acquire its German ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...